Alzheimer’s Matters, the official blog of the ADDF, features insights, perspectives and commentary on current topics of interest in Alzheimer’s disease and related drug discovery.

Trial of First Broad-Spectrum Drug for Neurodegeneration Seeking Volunteers


ADDF grantee Dr. Raymond Scott Turner is now recruiting patients for a Phase 2 clinical trial of nilotinib—a drug already FDA-approved for leukemia that is being testes as a treatment for Alzheimer’s disease.

Donor Spotlight: Joyce Cowin


Joyce Cowin, a longtime ADDF supporter, talks about why she has a new sense of hope about Alzheimer's treatments. She believes strongly that a victory in the fight against Alzheimer's "is inevitable and on the horizon."

Prevention: A Key to Conquering Alzheimer’s


Dr. Fillit explains the importance of prevention to the ADDF's mission and our current efforts, including clinical trials. 

Closing in on a Cure: Dr. Michela Gallagher and AGB101


Dr. Michela Gallagher of Agenebio and Johns Hopkins University is developing AGB101, which has the potential to prevent mild cognitive impairment from progressing to Alzheimer's disease.

Does Verubecestat Signal the End of the Amyloid Hypothesis?


Merck announces the end of another anti-amyloid drug trial, calling in to question the amyloid hypothesis and the fate of other anti-amyloid drugs.

Closing in on a Cure: Oryzon Genomics and ORY-2001


Discover ORY-2001, a revolutionary epigenetic therapy for Alzheimer's disease being developed by Oryzon Genomics in Barcelona, Spain. 

Top Five Alzheimer’s Advances in 2016


In 2016, we made 46 new grants totaling $16.3 million. This brought us to an important milestone—$100 million invested in drugs to prevent, treat, and ultimately cure Alzheimer’s. And we are closing in on a cure. Over the past year, we made great progress, as our top five advances demonstrate.

Closing in on a Cure: Dr. Frank Longo and C-31


We have supported over 20% of all the treatments for Alzheimer’s currently in clinical trials. One of the most promising of these is C-31, developed by Frank Longo, MD, PhD.

Striding Toward $100 Million on Giving Tuesday


Since 1998, the ADDF has invested $97 million in critical research and—with your #GivingTuesday donation—we will reach $100 million this year.

What Does the Failure of Solanezumab Mean?


Eli Lilly announced that its Alzheimer's drug solanezumab failed in its last phase 3 clinical trial. Howard Fillit, MD, discusses what this means for the field and for patients, and where we go from here.